[Current trends in medical therapy of gastroduodenal ulcer].
D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000627:therapeutic use; D005755:Gastrins / Q000037:antagonists & inhibitors; D006633:Histamine Antagonists / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008900:Mineral Waters; D009942:Organometallic Compounds / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000628:therapy; D013392:Sucralfate / Q000627:therapeutic use
D000863:Antacids; D000897:Anti-Ulcer Agents; D005755:Gastrins; D006633:Histamine Antagonists; D006635:Histamine H2 Antagonists; D008900:Mineral Waters; D009942:Organometallic Compounds; D010276:Parasympatholytics; D013392:Sucralfate; C002791:bismuth tripotassium dicitrate; D002229:Carbenoxolone
Attuali orientamenti di terapia medica dell'ulcera gastrica e duodenale.